Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias.

Bioengineered · 2022 · PMC9161826 · PMID 35322728

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Although there is no statistical difference between Hm3A4-Rap group and Hm3A4 group due to the small number of mice, a clear trend can be found.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.